Dyax Corp is a biopharmaceutical company. The Company is focused on Hereditary Angioedema (HAE) and other Plasma-Kallikrein-Mediated (PKM) Disorders, and licensing and funded research portfolio. The Company develops and commercializes treatments for hereditary angioedema. The Company discovered and developed KALBITOR, a plasma kallikrein inhibitor, and is selling it in the United States for the treatment of acute attacks of HAE. Additionally, it discovered and is developing DX-2930, a human monoclonal antibody inhibitor of plasma kallikrein. It also developed a biomarker assay that detects the activation of plasma kallikrein in patient blood. The Company has a portfolio of product candidates being developed by licensees using its phage display technology. This portfolio includes one approved product, CYRAMZA (ramucirumab), which is marketed by Eli Lilly and Company (Lilly), and multiple product candidates in various stages of clinical development.
Industry, Sector and Symbol
Industry N/A
Sub-IndustryBiotechnology
SectorN/A
SymbolNASDAQ:DYAX
CUSIP26746E10
Phone+1-617-2505769
Debt
Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net Margins-47.32%
Return on Equity-14.86%
Return on Assets-12.09%
Miscellaneous
EmployeesN/A
Outstanding Shares146,360,000
Dyax (NASDAQ:DYAX) Frequently Asked Questions
What is Dyax's stock symbol?
Dyax trades on the NASDAQ under the ticker symbol "DYAX."
How were Dyax's earnings last quarter?
Dyax Corp. (NASDAQ:DYAX) announced its quarterly earnings results on Wednesday, October, 28th. The biopharmaceutical company reported ($0.08) EPS for the quarter, meeting the Thomson Reuters' consensus estimate of ($0.08). The biopharmaceutical company had revenue of $24.70 million for the quarter, compared to analyst estimates of $24.96 million. Dyax had a negative return on equity of 14.86% and a negative net margin of 47.32%. Dyax's quarterly revenue was up 12.3% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($0.01) EPS. View Dyax's Earnings History.
Has Dyax been receiving favorable news coverage?
News coverage about DYAX stock has trended positive on Wednesday, according to Accern. The research firm rates the sentiment of press coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Dyax earned a media sentiment score of 0.29 on Accern's scale. They also assigned news headlines about the biopharmaceutical company an impact score of 45.18 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the near term.
How do I buy shares of Dyax?
Shares of DYAX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Dyax's stock price today?
One share of DYAX stock can currently be purchased for approximately $38.04.
How can I contact Dyax?
Dyax's mailing address is 55 Network Dr, BURLINGTON, MA 01803-2756, United States. The biopharmaceutical company can be reached via phone at +1-617-2505769.
MarketBeat Community Rating for Dyax (DYAX)
MarketBeat's community ratings are surveys of what our community members think about Dyax and other stocks. Vote "Outperform" if you believe DYAX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DYAX will underperform the S&P 500 over the long term. You may vote once every thirty days.
Dyax (NASDAQ:DYAX) Analyst Ratings History
| Date | Brokerage | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
(Data available from 4/25/2016 forward)
Dyax (NASDAQ:DYAX) Earnings History and Estimates Chart
Dyax (NASDAQ DYAX) Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 10/28/2015 | Q315 | ($0.08) | ($0.08) | $24.96 million | $24.70 million | View | N/A |  |
| 7/29/2015 | Q215 | ($0.04) | ($0.06) | $23.40 million | $264.00 million | View | Listen | |
| 4/29/2015 | Q115 | ($0.05) | ($0.05) | $21.79 million | $20.40 million | View | N/A | |
| 2/24/2015 | Q414 | ($0.04) | ($0.02) | $19.90 million | $26.00 million | View | N/A | |
| 10/28/2014 | Q314 | ($0.06) | ($0.01) | $15.70 million | $22.00 million | View | N/A | |
| 7/29/2014 | Q214 | ($0.05) | ($0.02) | $14.13 million | $19.59 million | View | N/A | |
| 4/30/2014 | Q1 2014 | ($0.05) | ($0.05) | $13.65 million | $14.12 million | View | N/A | |
| 2/28/2014 | Q413 | ($0.04) | ($0.02) | $15.84 million | $16.90 million | View | N/A | |
| 10/22/2013 | Q3 2013 | ($0.05) | ($0.06) | $14.80 million | $13.69 million | View | N/A | |
| 7/24/2013 | Q2 2013 | ($0.06) | ($0.08) | $13.77 million | $11.34 million | View | N/A | |
| 4/25/2013 | Q1 2013 | ($0.05) | ($0.11) | $16.62 million | $12.04 million | View | N/A | |
| 2/13/2013 | Q4 2012 | ($0.05) | ($0.05) | | | View | N/A | |
| 10/24/2012 | Q3 2012 | ($0.08) | ($0.05) | | | View | N/A | |
| 7/19/2012 | Q2 2012 | ($0.09) | ($0.08) | | | View | N/A | |
| 4/24/2012 | Q1 2012 | ($0.09) | ($0.10) | | | View | N/A | |
| 2/22/2012 | Q4 2011 | ($0.10) | ($0.14) | | | View | N/A | |
| 10/27/2011 | Q3 2011 | ($0.13) | ($0.10) | | | View | N/A | |
| 4/27/2011 | Q1 2011 | ($0.11) | ($0.11) | | | View | N/A | |
| 2/23/2011 | Q4 2010 | ($0.11) | ($0.09) | | | View | N/A | |
| 10/27/2010 | Q3 2010 | ($0.13) | ($0.11) | | | View | N/A | |
| 7/28/2010 | Q2 2010 | ($0.14) | ($0.05) | | | View | N/A | |
| 4/28/2010 | Q1 2010 | ($0.15) | $0.01 | | | View | N/A | |
| 2/17/2010 | Q4 2009 | ($0.17) | ($0.14) | | | View | N/A | |
| 10/28/2009 | Q3 2009 | ($0.20) | ($0.16) | | | View | N/A | |
| 7/22/2009 | Q2 2009 | ($0.24) | ($0.23) | | | View | N/A | |
| 4/22/2009 | Q1 2009 | ($0.27) | ($0.36) | | | View | N/A | |
| 2/25/2009 | Q4 2008 | ($0.17) | $0.10 | | | View | N/A | |
| 10/22/2008 | Q3 2008 | ($0.19) | ($0.29) | | | View | N/A | |
| 7/23/2008 | Q2 2008 | ($0.27) | ($0.41) | | | View | N/A | |
| 4/24/2008 | Q1 2008 | $0.07 | ($0.35) | | | View | N/A | |
| 2/27/2008 | Q4 2007 | ($0.29) | ($0.05) | | | View | N/A | |
(Earnings results data provided by Zacks Investment Research)
Dyax (NASDAQ:DYAX) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Dyax (NASDAQ DYAX) Insider Trading and Institutional Ownership History
Dyax (NASDAQ DYAX) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 9/10/2015 | Thomas L Kempner | Director | Sell | 6,000 | $22.47 | $134,820.00 | 55,041 | |
| 8/28/2015 | Thomas L Kempner | Director | Sell | 17,947 | $23.83 | $427,677.01 | 55,041 | |
| 8/18/2015 | Thomas L Kempner | Director | Sell | 18,035 | $23.83 | $429,774.05 | | |
| 8/13/2015 | Thomas L Kempner | Director | Sell | 4,848 | $23.81 | $115,430.88 | | |
| 7/20/2015 | Henry E Blair | Director | Sell | 50,000 | $27.05 | $1,352,500.00 | | |
| 6/8/2015 | David J Mclachlan | Director | Sell | 75,000 | $25.63 | $1,922,250.00 | | |
| 3/6/2015 | Andrew D Ashe | EVP | Sell | 2,400 | $15.50 | $37,200.00 | | |
| 3/5/2015 | Burt A Adelman | CMO | Sell | 9,375 | $15.66 | $146,812.50 | | |
| 3/5/2015 | George V Migausky | CFO | Sell | 5,000 | $15.86 | $79,300.00 | | |
| 3/5/2015 | Gustav Christensen | CEO | Sell | 6,250 | $15.86 | $99,125.00 | | |
| 2/26/2015 | Andrew D Ashe | EVP | Sell | 1,500 | $15.34 | $23,010.00 | | |
| 1/2/2015 | Burt A Adelman | CMO | Sell | 75,000 | $14.05 | $1,053,750.00 | | |
| 12/5/2014 | Thomas L Kempner | Director | Sell | 14,764 | $13.79 | $203,595.56 | | |
| 11/21/2014 | Thomas L Kempner | Director | Sell | 100,000 | $13.20 | $1,320,000.00 | | |
| 9/12/2014 | Thomas L Kempner | Director | Sell | 12,400 | $11.00 | $136,400.00 | | |
| 8/26/2014 | Thomas L Kempner | Director | Sell | 37,000 | $10.39 | $384,430.00 | | |
| 8/19/2014 | Thomas L Kempner | Director | Sell | 113,755 | $9.67 | $1,100,010.85 | | |
| 8/7/2014 | Thomas L Kempner | Director | Sell | 33,190 | $9.25 | $307,007.50 | | |
| 6/13/2014 | George V Migausky | CFO | Sell | 16,000 | $8.26 | $132,160.00 | | |
| 3/5/2014 | Henry Blair | Director | Sell | 150,000 | $10.46 | $1,569,000.00 | 353,722 | |
| 3/3/2014 | Andrew Ashe | EVP | Sell | 30,000 | $10.00 | $300,000.00 | 36,277 | |
| 3/3/2014 | Burt Adelman | CMO | Sell | 55,000 | $9.68 | $532,400.00 | 37,500 | |
| 2/26/2014 | Andrew Ashe | VP | Sell | 2,723 | $10.10 | $27,502.30 | 12,277 | |
| 12/5/2013 | Thomas Kempner | Director | Sell | 400,000 | $8.37 | $3,348,000.00 | 27,311 | |
| 8/13/2013 | Andrew Ashe | VP | Sell | 32,500 | $4.30 | $139,750.00 | 15,000 | |
| 5/16/2013 | Marc D Kozin | Director | Buy | 22,971 | $2.46 | $56,508.66 | | |
| 2/25/2013 | George V Migausky | CFO | Sell | 4,275 | $3.28 | $14,022.00 | | |
| 2/25/2013 | Ivana Magovcevic | COO | Sell | 4,015 | $3.24 | $13,008.60 | | |
(Data available from 1/1/2013 forward)
Dyax (NASDAQ DYAX) News Headlines
| Source: |
|
Dyax (NASDAQ:DYAX) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Dyax (NASDAQ:DYAX) Income Statement, Balance Sheet and Cash Flow Statement
Dyax (NASDAQ DYAX) Stock Chart for Wednesday, April, 25, 2018
Loading chart…
